• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

AkaRx

edit

AkaRx, Inc., a biopharmaceutical company, develops therapeutic treatments for unmet medical needs. Its product includes AKR-501, an orally-available small molecule for use in the treatment of thrombocytopenia. The company was founded in 2005 and is headquartered in Paramus, New Jersey.

Recent Milestones

edit

• 
  AkaRx was acquired by Eisai for $255M. (1/7/10)
  Posted 1/13/10 at 4:42am via co.jp
• 
  AkaRx received $26.1M in Venture Round funding. (1/7/10)
  Posted 1/8/10 at 2:35am via dowjones.com
• 
  AkaRx added Robert E. Desjardins as Co-Founder .
  Posted 1/8/10 at 2:32am

Videos

Screenshots

edit

Sources

1. Eisai Completes Acquisition of AkaRx, Inc. in the United States (eisai.co.jp) [edit]
2. Eisai's $255M AkaRx Buy Creates Returns For InterWest, Sutter Hill (fis.dowjones.com) [edit]